Synthesis of eugenol-derived glucosides and evaluation of their ability in inhibiting the angiotensin converting enzyme

Nat Prod Res. 2022 May;36(9):2246-2253. doi: 10.1080/14786419.2020.1827399. Epub 2020 Oct 9.

Abstract

We report here a series of glucosides which are active as inhibitors of the angiotensin converting enzyme (ACE). They are structurally related to the natural compound eugenol and exhibited significant inhibition values. Their syntheses were expeditious and we could obtain informative docking plots of them complexed to this enzyme. A glucoside derived from eugenol, carrying a carboxylic group in the aglycone, was the most active of them (with an IC50 of 0.4 mM) and showed good binding energies in docking studies with ACE. Moreover, computational prediction of toxicity risks, physicochemical properties and drug score show that the glucoside derivative of eugenol is a suitable compound for optimisation studies aimed at finding new drug candidates.

Keywords: Glucosides; angiotensin converting enzyme; enzyme inhibitors; eugenol.

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / chemistry
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Eugenol* / pharmacology
  • Glucosides / chemistry
  • Glucosides / pharmacology
  • Molecular Docking Simulation
  • Peptidyl-Dipeptidase A* / chemistry
  • Peptidyl-Dipeptidase A* / metabolism

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Glucosides
  • Eugenol
  • Peptidyl-Dipeptidase A